Fertigyn HP: Advanced hCG Formulation for Precision Hormone Therapy
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $28.48 | $85.45 (0%) | 🛒 Add to cart |
| 5 | $26.14
Best per ampoule | $142.41 $130.69 (8%) | 🛒 Add to cart |
| Product dosage: 2000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $16.75 | $50.26 (0%) | 🛒 Add to cart |
| 5 | $15.08
Best per ampoule | $83.77 $75.40 (10%) | 🛒 Add to cart |
| Product dosage: 5000iu | |||
|---|---|---|---|
| Package (num) | Per ampoule | Price | Buy |
| 3 | $18.43 | $55.29 (0%) | 🛒 Add to cart |
| 5 | $17.09
Best per ampoule | $92.15 $85.45 (7%) | 🛒 Add to cart |
Fertigyn HP is a highly purified human chorionic gonadotropin (hCG) formulation designed for medical use in fertility treatment and hormonal regulation. As a recombinant DNA-derived hormone, it offers exceptional purity, consistency, and bioavailability, making it a trusted choice among endocrinologists and reproductive specialists. Its high-potency formulation ensures reliable biological activity, supporting critical therapeutic outcomes in both male and female patients. This product is indicated under professional supervision for specific endocrine dysfunctions and assisted reproductive technologies.
Features
- Recombinant DNA-derived human chorionic gonadotropin (hCG)
- High purity formulation (>99% by HPLC)
- Lyophilized powder in sterile vials
- Available in 2000 IU, 5000 IU, and 10,000 IU strengths
- Packaged with bacteriostatic water for injection
- Precisely calibrated bioactivity
- Low endotoxin levels (<5 EU/mg)
- Manufactured under cGMP conditions
Benefits
- Supports ovulation induction in anovulatory women
- Promotes testicular testosterone production in hypogonadotropic hypogonadism
- Aids in corpus luteum maintenance during luteal phase support
- Facilitates spermatogenesis in male infertility cases
- Provides predictable pharmacokinetic profile for dosing accuracy
- Reduces batch-to-batch variability through recombinant technology
Common use
Fertigyn HP is primarily employed in reproductive medicine and endocrine disorders. In female patients, it is used for ovulation induction in conjunction with other gonadotropins as part of controlled ovarian stimulation protocols for assisted reproductive technology (ART). It is also indicated for the treatment of anovulation in women with polycystic ovary syndrome (PCOS) who have failed to respond to clomiphene citrate. In male patients, it is used to stimulate testosterone production in prepubertal cryptorchidism and hypogonadotropic hypogonadism. Off-label uses include weight loss protocols in combination with very low-calorie diets, though this application remains controversial and requires careful medical supervision.
Dosage and direction
Dosage must be individualized based on therapeutic indication, patient response, and laboratory parameters. For ovulation induction: 5,000–10,000 IU as a single intramuscular injection 24–48 hours after the last dose of follicle-stimulating hormone (FSH) or menotropins. For male hypogonadism: 1,000–4,000 IU administered intramuscularly 2–3 times weekly for several months. Reconstitute with provided diluent; gently swirl until clear solution forms. Do not shake vigorously. Administer via deep intramuscular injection using aseptic technique. Rotate injection sites to prevent lipoatrophy. Discard any unused portion as the product contains no preservatives.
Precautions
Use under strict medical supervision with regular monitoring of ovarian size via ultrasonography to prevent ovarian hyperstimulation syndrome (OHSS). Monitor estradiol levels in women during stimulation cycles. In male patients, monitor testosterone levels, hematocrit, and prostate-specific antigen (PSA). Use caution in patients with history of seizures, migraine, asthma, or cardiac/renal impairment. May cause fluid retention; use cautiously in patients predisposed to thromboembolic events. Not recommended for patients with hormone-dependent malignancies. Pregnancy must be excluded before initiation in women.
Contraindications
Hypersensitivity to hCG or any component of the formulation. Primary testicular failure in males. Precocious puberty. Uncontrolled thyroid or adrenal dysfunction. Ovarian cyst or enlargement not due to polycystic ovary syndrome. Abnormal uterine bleeding of undetermined origin. Ovarian, uterine, or breast carcinoma. Pituitary tumor or hyperplasia. Thrombophlebitis or thromboembolic disorders.
Possible side effect
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions (pain, erythema, swelling)
- Headache
- Fatigue
- Irritability
- Depression
- Gynecomastia in males
- Peripheral edema
- Thromboembolic events (rare)
- Allergic reactions (urticaria, rash)
- Precocious puberty in children
Drug interaction
May enhance effects of corticosteroids. Concurrent use with gonadotropin-releasing hormone (GnRH) analogs may alter response. Androgens and estrogens may interfere with therapeutic effects. Drugs affecting pituitary-gonadal axis (such as psychotropic agents, steroids, or spironolactone) may modify response. No formal interaction studies with CYP450 substrates.
Missed dose
If a dose is missed, administer as soon as possible. However, if it is near the time for the next dose, skip the missed dose and resume regular dosing schedule. Do not double doses to make up for a missed dose. In ovarian stimulation protocols, contact the treating physician immediately as timing is critical for successful ovulation induction.
Overdose
Overdose may lead to severe OHSS characterized by ovarian enlargement, ascites, pleural effusion, and hemoconcentration. In males, excessive dosing may cause exaggerated androgen effects including acne, hirsutism, and aggressive behavior. Treatment is symptomatic and supportive. In cases of severe OHSS, hospitalization may be required for fluid management, paracentesis, and thromboprophylaxis.
Storage
Store unopened vials at 2–8°C (36–46°F). Do not freeze. Protect from light. After reconstitution, use immediately or store at 2–8°C for up to 30 days if using bacteriostatic water. Do not use if solution is discolored or contains particulate matter. Keep out of reach of children.
Disclaimer
This information is for medical professionals only. Fertigyn HP is a prescription medication requiring proper diagnosis and supervision. This document does not replace professional medical advice, diagnosis, or treatment. Always consult approved prescribing information and current clinical guidelines before administration. The manufacturer is not liable for improper use or dosing errors.
Reviews
“Fertigyn HP has demonstrated consistent results in our IVF program. The recombinant formulation offers reliable bioavailability and fewer batch variations compared to urinary-derived products.” – Reproductive Endocrinologist, Massachusetts
“Using Fertigyn HP for hypogonadotropic hypogonadism has provided predictable testosterone response with minimal side effects. The lyophilized form maintains stability well in clinical settings.” – Andrologist, Texas
“Patients tolerate the IM injections well, and we’ve observed excellent ovulation rates in PCOS patients resistant to other modalities. Monitoring remains crucial given OHSS risk.” – Fertility Specialist, California